BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Petit J, Cercueil J, Loffroy R, Denimal D, Bouillet B, Fourmont C, Chevallier O, Duvillard L, Vergès B. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study. The Journal of Clinical Endocrinology & Metabolism 2016. [DOI: 10.1210/jc.2016-2775] [Cited by in Crossref: 46] [Cited by in F6Publishing: 70] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, Guo J. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol 2023;13. [DOI: 10.3389/fendo.2022.1087260] [Reference Citation Analysis]
2 Yang Z, Tian R, Zhang X, Cai J, She Z, Li H. Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction. Front Cardiovasc Med 2023;9. [DOI: 10.3389/fcvm.2022.1120085] [Reference Citation Analysis]
3 Gallwitz B. Die Rolle inkretinbasierter Therapien bei NAFLD/NASH. CV 2022;22:24-27. [DOI: 10.1007/s15027-022-2927-z] [Reference Citation Analysis]
4 Suri J, Borja S, Lim JK. Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis. World J Gastroenterol 2022; 28(35): 5129-5140 [DOI: 10.3748/wjg.v28.i35.5129] [Reference Citation Analysis]
5 Tsankof A, Neokosmidis G, Koureta E, Veneti S, Cholongitas E, Tziomalos K. Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease? Front Endocrinol 2022;13:984041. [DOI: 10.3389/fendo.2022.984041] [Reference Citation Analysis]
6 Omanovic Kolaric T, Kizivat T, Mihaljevic V, Zjalic M, Bilic-Curcic I, Kuna L, Smolic R, Vcev A, Wu GY, Smolic M. Liraglutide Exerts Protective Effects by Downregulation of PPARγ, ACSL1 and SREBP-1c in Huh7 Cell Culture Models of Non-Alcoholic Steatosis and Drug-Induced Steatosis. Curr Issues Mol Biol 2022;44:3465-80. [PMID: 36005135 DOI: 10.3390/cimb44080239] [Reference Citation Analysis]
7 Nascè A, Gariani K, Jornayvaz FR, Szanto I. NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook. Antioxidants (Basel) 2022;11:1131. [PMID: 35740032 DOI: 10.3390/antiox11061131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Schwartz S, Lucas J, DeLegge MH. Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice. touchREV Endocrinol 2021;17:112-20. [PMID: 35118457 DOI: 10.17925/EE.2021.17.2.112] [Reference Citation Analysis]
9 Laurindo LF, Barbalho SM, Guiguer EL, da Silva Soares de Souza M, de Souza GA, Fidalgo TM, Araújo AC, de Souza Gonzaga HF, de Bortoli Teixeira D, de Oliveira Silva Ullmann T, Sloan KP, Sloan LA. GLP-1a: Going beyond Traditional Use. Int J Mol Sci 2022;23:739. [PMID: 35054924 DOI: 10.3390/ijms23020739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
10 F. Lange N, Dufour J. Spezifische Therapie – neue Medikamente. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_21] [Reference Citation Analysis]
11 Zhu Y, Xu J, Zhang D, Mu X, Shi Y, Chen S, Wu Z, Li S. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 2021;12:769069. [PMID: 34956080 DOI: 10.3389/fendo.2021.769069] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
12 Martianova MV, Laevskaya MY, Meltonian AR, Bregovskiy VB, Babenko AY. Direct comparison of the effects of liraglutide and dulaglutide on the dynamics of scales and markers of hepatic fibrosis. jour 2021. [DOI: 10.31146/1682-8658-ecg-194-10-82-90] [Reference Citation Analysis]
13 Mărginean CO, Meliț LE, Săsăran MO. Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic. Biomedicines 2021;9:1866. [PMID: 34944682 DOI: 10.3390/biomedicines9121866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J Hepatol 2021; 13(11): 1584-1610 [PMID: 34904031 DOI: 10.4254/wjh.v13.i11.1584] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
16 Li X, Wu X, Jia Y, Fu J, Zhang L, Jiang T, Liu J, Wang G. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. J Diabetes Res 2021;2021:3715026. [PMID: 34660809 DOI: 10.1155/2021/3715026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
17 Van Gaal LF, Mertens J, Francque S, De Block C. Therapeutic approaches for non-alcoholic steatohepatitis. Ther Adv Endocrinol Metab 2021;12:20420188211034300. [PMID: 34497708 DOI: 10.1177/20420188211034300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol 2021;18:599-612. [PMID: 33972770 DOI: 10.1038/s41575-021-00448-y] [Cited by in Crossref: 129] [Cited by in F6Publishing: 113] [Article Influence: 64.5] [Reference Citation Analysis]
19 Brown E, Hydes T, Hamid A, Cuthbertson DJ. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Clin Ther 2021;43:1476-504. [PMID: 34446271 DOI: 10.1016/j.clinthera.2021.07.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
20 Bagriy AE, Zubov AD, Khomenko MV, Mikhailichenko ES, Pylaeva EA, Khaustova NA, Bryukhovetskaya EV. Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2021;31:14-26. [DOI: 10.22416/1382-4376-2021-31-2-14-26] [Reference Citation Analysis]
21 Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 2021;18:373-92. [PMID: 33568794 DOI: 10.1038/s41575-020-00408-y] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 46.0] [Reference Citation Analysis]
22 Ghazanfar H, Kandhi SD, Nawaz I, Javed N, Abraham MC, Farag M, Mahasamudram J, Patel VB, Altaf F, Patel H. Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article. Cureus 2021;13:e15141. [PMID: 34164242 DOI: 10.7759/cureus.15141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
23 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
24 Lafferty RA, O'Harte FPM, Irwin N, Gault VA, Flatt PR. Proglucagon-Derived Peptides as Therapeutics. Front Endocrinol (Lausanne) 2021;12:689678. [PMID: 34093449 DOI: 10.3389/fendo.2021.689678] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
25 Kozawa J, Shimomura I. Ectopic Fat Accumulation in Pancreas and Heart. J Clin Med 2021;10:1326. [PMID: 33806978 DOI: 10.3390/jcm10061326] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
26 Köseoğlu D, Koparal SS, Özdemir Başer Ö, Berker D. Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study. Turk J Med Sci 2021;51:167-74. [PMID: 32892547 DOI: 10.3906/sag-2004-154] [Reference Citation Analysis]
27 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 24.0] [Reference Citation Analysis]
28 Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:221-35. [PMID: 33317243 DOI: 10.3350/cmh.2020.0239] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
29 Guo W, Tian W, Lin L, Xu X. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. Diabetes Research and Clinical Practice 2020;170:108487. [DOI: 10.1016/j.diabres.2020.108487] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
30 Fang Y, Ji L, Zhu C, Xiao Y, Zhang J, Lu J, Yin J, Wei L. Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway. Front Cell Dev Biol 2020;8:602574. [PMID: 33330497 DOI: 10.3389/fcell.2020.602574] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
31 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 12.7] [Reference Citation Analysis]
32 Polyzos SA, Perakakis N, Boutari C, Kountouras J, Ghaly W, Anastasilakis AD, Karagiannis A, Mantzoros CS. Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. J Clin Endocrinol Metab 2020;105:dgz172. [PMID: 31690932 DOI: 10.1210/clinem/dgz172] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
33 Vedtofte L, Bahne E, Foghsgaard S, Bagger JI, Andreasen C, Strandberg C, Gørtz PM, Holst JJ, Grønbæk H, Svare JA, Clausen TD, Mathiesen ER, Damm P, Gluud LL, Knop FK, Vilsbøll T. One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. J Clin Med 2020;9:E3213. [PMID: 33036179 DOI: 10.3390/jcm9103213] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
34 Robinson KE, Shah VH. Pathogenesis and pathways: nonalcoholic fatty liver disease & alcoholic liver disease. Transl Gastroenterol Hepatol 2020;5:49. [PMID: 33073044 DOI: 10.21037/tgh.2019.12.05] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
35 Hanif H, Khan MM, Ali MJ, Shah PA, Satiya J, Lau DTY, Aslam A. A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. Microorganisms 2020;8:E1526. [PMID: 33020450 DOI: 10.3390/microorganisms8101526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 2020;69:1877-84. [PMID: 32381514 DOI: 10.1136/gutjnl-2019-319104] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 26.3] [Reference Citation Analysis]
37 Teshome G, Ambachew S, Fasil A, Abebe M. Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review. Hepat Med 2020;12:139-51. [PMID: 33061687 DOI: 10.2147/HMER.S265631] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
38 Fang T, Huang S, Chen Y, Chen Z, Chen J, Hu W. Glucagon Like Peptide-1 Receptor Agonists Alters Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model. Exp Clin Endocrinol Diabetes. 2020;. [PMID: 32961563 DOI: 10.1055/a-1240-4936] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
39 Kuchay MS, Krishan S, Mishra SK, Choudhary NS, Singh MK, Wasir JS, Kaur P, Gill HK, Bano T, Farooqui KJ, Mithal A. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia 2020;63:2434-45. [PMID: 32865597 DOI: 10.1007/s00125-020-05265-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 18.7] [Reference Citation Analysis]
40 Sofogianni A, Filippidis A, Chrysavgis L, Tziomalos K, Cholongitas E. Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update. World J Hepatol 2020; 12(8): 493-505 [PMID: 32952876 DOI: 10.4254/wjh.v12.i8.493] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
41 Kim KS, Lee BW. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clin Mol Hepatol 2020;26:430-43. [PMID: 32791578 DOI: 10.3350/cmh.2020.0137] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
42 Svegliati-Baroni G, Patrício B, Lioci G, Macedo MP, Gastaldelli A. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. Int J Mol Sci 2020;21:E5820. [PMID: 32823659 DOI: 10.3390/ijms21165820] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
43 Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).J Diabetes Res. 2020;2020:3920196. [PMID: 32832560 DOI: 10.1155/2020/3920196] [Cited by in Crossref: 55] [Cited by in F6Publishing: 65] [Article Influence: 18.3] [Reference Citation Analysis]
44 Shiomi M, Tanaka Y, Takada T, Otori K. Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index. JGH Open 2020;4:995-1001. [PMID: 33102775 DOI: 10.1002/jgh3.12384] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
45 Dougherty JA, Guirguis E, Thornby KA. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease. Ann Pharmacother 2021;55:65-79. [PMID: 32571083 DOI: 10.1177/1060028020935105] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
46 Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 15.3] [Reference Citation Analysis]
47 Lv X, Dong Y, Hu L, Lu F, Zhou C, Qin S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. Endocrinol Diabetes Metab 2020;3:e00163. [PMID: 32704576 DOI: 10.1002/edm2.163] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
48 Cigrovski Berkovic M, Virovic-Jukic L, Bilic-Curcic I, Mrzljak A. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World J Gastroenterol 2020; 26(21): 2740-2757 [PMID: 32550751 DOI: 10.3748/wjg.v26.i21.2740] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
49 Mittag-Roussou V, Wagenpfeil S, Lammert F, Stokes CS. Noninvasive monitoring of liver fat during treatment with GLP-1 analogues and SGLT-2 inhibitors in a real-world setting. Endocrinol Diabetes Metab 2020;3:e00131. [PMID: 32704556 DOI: 10.1002/edm2.131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
50 Zhang N, Tao J, Gao L, Bi Y, Li P, Wang H, Zhu D, Feng W. Liraglutide Attenuates Nonalcoholic Fatty Liver Disease by Modulating Gut Microbiota in Rats Administered a High-Fat Diet. Biomed Res Int 2020;2020:2947549. [PMID: 32149099 DOI: 10.1155/2020/2947549] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
51 Pan CS, Stanley TL. Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. Front Endocrinol (Lausanne) 2020;11:70. [PMID: 32153507 DOI: 10.3389/fendo.2020.00070] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
52 Breder I, Sposito AC. GLP1-Receptor Agonists in Diabetes: Drugs, General Effects, and Cardiovascular Impact. Obesity and Diabetes 2020. [DOI: 10.1007/978-3-030-53370-0_51] [Reference Citation Analysis]
53 Noureddin M, Muthiah MD, Sanyal AJ. Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00105. [PMID: 33102791 DOI: 10.1002/edm2.105] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
54 Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int 2020;14:8-23. [PMID: 31802390 DOI: 10.1007/s12072-019-10001-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
55 Bizino MB, Jazet IM, de Heer P, van Eyk HJ, Dekkers IA, Rensen PCN, Paiman EHM, Lamb HJ, Smit JW. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. Diabetologia 2020;63:65-74. [PMID: 31690988 DOI: 10.1007/s00125-019-05021-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 8.8] [Reference Citation Analysis]
56 Ismaiel A, Dumitraşcu DL. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Front Med (Lausanne) 2019;6:202. [PMID: 31616668 DOI: 10.3389/fmed.2019.00202] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 15.5] [Reference Citation Analysis]
57 Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep 2019;1:312-28. [PMID: 32039382 DOI: 10.1016/j.jhepr.2019.07.002] [Cited by in Crossref: 139] [Cited by in F6Publishing: 148] [Article Influence: 34.8] [Reference Citation Analysis]
58 Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, Li Y, Dou J, Yang W, Qin G, Yuan H, Xiao X, Luo S, Shan Z, Deng H, Tan Y, Xu F, Xu W, Zeng L, Kang Z, Weng J. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Hepatology 2019;69:2414-26. [PMID: 30341767 DOI: 10.1002/hep.30320] [Cited by in Crossref: 107] [Cited by in F6Publishing: 101] [Article Influence: 26.8] [Reference Citation Analysis]
59 Jung CH, Mok JO. The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. J Obes Metab Syndr 2019;28:18-29. [PMID: 31089576 DOI: 10.7570/jomes.2019.28.1.18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
60 Kothari S, Dhami-Shah H, Shah SR. Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease. J Clin Exp Hepatol 2019;9:723-30. [PMID: 31889754 DOI: 10.1016/j.jceh.2019.06.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
61 Rowlands J, Heng J, Newsholme P, Carlessi R. Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Front Endocrinol (Lausanne) 2018;9:672. [PMID: 30532733 DOI: 10.3389/fendo.2018.00672] [Cited by in Crossref: 117] [Cited by in F6Publishing: 119] [Article Influence: 23.4] [Reference Citation Analysis]
62 Seghieri M, Christensen AS, Andersen A, Solini A, Knop FK, Vilsbøll T. Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. Front Endocrinol (Lausanne) 2018;9:649. [PMID: 30459715 DOI: 10.3389/fendo.2018.00649] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 8.8] [Reference Citation Analysis]
63 Shin SK, Cho HW, Song SE, Song DK. Catalase and nonalcoholic fatty liver disease. Pflugers Arch 2018;470:1721-37. [PMID: 30120555 DOI: 10.1007/s00424-018-2195-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
64 Petit JM, Vergès B. GLP-1 receptor agonists in NAFLD. Diabetes Metab 2017;43 Suppl 1:2S28-33. [PMID: 28431668 DOI: 10.1016/S1262-3636(17)30070-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
65 Yang SH, Xu RX, Cui CJ, Wang Y, Du Y, Chen ZG, Yao YH, Ma CY, Zhu CG, Guo YL, Wu NQ, Sun J, Chen BX, Li JJ. Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism. Cardiovasc Diabetol 2018;17:48. [PMID: 29618348 DOI: 10.1186/s12933-018-0689-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
66 Germain N, Khalfallah Y, Estour B, Galusca B. Insulin tolerance test predicts non response vs. sustained efficacy of Liraglutide on glycemic control in type 2 diabetes patients: A prospective real-world setting study. Diabetes Research and Clinical Practice 2018;137:20-7. [DOI: 10.1016/j.diabres.2017.12.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
67 Cusi K. Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes. Contemporary Diabetes 2018. [DOI: 10.1007/978-3-319-61013-9_4] [Reference Citation Analysis]
68 Tiwari J, Gupta G, Dahiya R, Pabreja K, Kumar Sharma R, Mishra A, Dua K. Recent update on biological activities and pharmacological actions of liraglutide. EXCLI J 2017;16:742-7. [PMID: 28827989 DOI: 10.17179/excli2017-323] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
69 Bonnet F. GLP-1 receptor agonist confer target organ protection in type 2 diabetes. Diabetes & Metabolism 2017;43:2S1-2. [DOI: 10.1016/s1262-3636(17)30066-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
70 Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J. Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. J Clin Transl Hepatol 2017;5:67-75. [PMID: 28507929 DOI: 10.14218/JCTH.2016.00061] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
71 Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13:297-310. [PMID: 28218263 DOI: 10.1038/nrneph.2017.16] [Cited by in Crossref: 148] [Cited by in F6Publishing: 160] [Article Influence: 24.7] [Reference Citation Analysis]
72 Rameshrad M, Razavi BM, Lalau JD, De Broe ME, Hosseinzadeh H. An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning. Iran J Basic Med Sci 2020;23:556-68. [PMID: 32742592 DOI: 10.22038/ijbms.2020.41638.9832] [Cited by in F6Publishing: 2] [Reference Citation Analysis]